Another week, another investor conference on the approach. It’s a bio conference this time, and these are always a big deal, and stocks in whatever industry the conference pertains to will usually respond positively. Companies persuade investors to buy in with impressive presentations on profitability and upcoming developments. But the BIO CEO & Investor Conference 2018, coming up on February 12th, is set to be particularly important.
BIO 2018 is a platform for Biotech firms to step up and impress, and with pharmaceutical shares repeatedly showing up on hot stock lists, the industry is always worth keeping an eye on. Usually, investors will have to be either very quick on the ball to buy in, or follow drug trial developments carefully to know when a rise is on the way. This conference will assuredly make it easier for shareholders, potential or current, to decide where to put their cash.
>> Corbus Pharmaceuticals Stock Continues to Grow
Presenting companies are selected from an application process and consist of small-to-large market cap sizes. In light of recent headlines and research, here are three companies presenting at the conference to keep an eye on:
Anavex Life Sciences Corp. (NASDAQ:AVXL): Phase III trial, Wilder Stage, Monday 12th, 9:45am
Anavex is a clinical stage company primarily engaged in the treatment of neurodegenerative and neurodevelopmental diseases such as Alzheimer’s and central nervous system (CNS) diseases. Its lead product, ANAVEX 2-73, recently completed a phase 2a clinical trial during which it was investigated for the treatment of Alzheimer’s. In addition, Annavex was awarded one of three ‘Buzz of BIO’ awards ahead of the conference this year, meaning it will have heightened exposure on the day – useful for making connections – as well as complimentary conference registration and company presentation. To top it all off, Anavex has a total of five products in its pipeline. Despite all of this exceedingly promising news, Anavex has seen poor stock performance in the last 52 weeks, with values falling -40.6% from this time last year. Hopefully, the BIO conference will turn this around. Shares are currently valued at $2.83 USD, bringing Anavex’s market cap to $125.1M.
CytRx Corporation (NASDAQ:CYTR): NDA/In-Review, Odets stage, Monday 12th, 10:15am
On the 17th January this year, CytRx announced that aldoxorubin, a drug it developed, was dosed to a patient in a phase 1b trial conducted by Nantcell, Inc. to investigate its efficacy in the treatment of pancreatic cancer. In the week following the news, shares in CytRx increased 26.18%. Before that, the company presented at the Biotech Showcase 2018 in San Francisco. The good news follows a disappointing 2017 for CytRx amid reports of a 3Q loss. CytRx primarily focuses on drugs for cancer treatment, and it will be interesting to see if it can continue this year’s success streak. Shares are still riding down last week’s surge, currently valued at $1.83 USD and bringing their market cap to $50.5M USD
>> Imprimis Pharmaceuticals Shares Rallied on Glaucoma Drugs
RedHill Biopharma Ltd. (NASDAQ:RDHL): Phase III trial, Ziegfeld stage, Monday 12th, 10:45am
Israel-based RedHill Biopharma, a biopharm company focused on late clinical-stage development of treatments for gastrointestinal diseases and cancer, saw a huge increase in stock value a few days ago. No one is quite sure why, but it’s possibly on the heels of news a couple of weeks before, when RedHill announced the final results of a Phase II clinical study of its drug BEKINDA 12 mg (RHB-102) on irritable bowel syndrome. Redhill also has the largest drug development pipeline out of the companies listed here with a total of nine, three of which are successfully marketed. Stocks are still riding down from a month-high of $6.94 earlier in January, sitting at $6.14 currently. This is still a good deal up from back in December, when prices reached a 52-week low of $4.58.
Remember, this list is not an absolute endorsement, and the success of these companies at the February conference is not necessarily guaranteed. But do keep an eye open, as share prices may spike as the conference passes.
Image source: Biotech.ca
